CURRENT AFFAIRS

Detailed explanation-1: -The US Food and Drug Administration (FDA) has approved lecanemab, the second-ever treatment for Alzheimer’s disease that is intended to tackle the root of the condition and the slow cognitive decline that results.

Detailed explanation-2: -Lecanemab works by removing a sticky protein from the brain that is believed to cause Alzheimer’s disease to advance. “It’s very exciting because this is the first treatment in our history that shows an unequivocal slowing of decline in Alzheimer’s disease, ” says Dr. van Dyck.

Detailed explanation-3: -Dementia Care – Netherlands The Netherlands has proven itself about as innovative as they come in terms of dementia care across the globe. In fact, one of the most popular and widely known dementia care communities is located outside of Amsterdam.

Detailed explanation-4: -The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company that also developed the first symptomatic treatment for Alzheimer’s 25 years ago.

Detailed explanation-5: -Donepezil (Aricept®): approved to treat all stages of Alzheimer’s disease. Rivastigmine (Exelon®): approved for mild-to-moderate Alzheimer’s as well as mild-to-moderate dementia associated with Parkinson’s disease. Galantamine (Razadyne®): approved for mild-to-moderate stages of Alzheimer’s disease.